Artesunate, as an Hsp90 inhibitor, inhibits the proliferation of Burkitt’s lymphoma cells by inhibiting AKT and ERK
Authors:
Open Access
- 31 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1218467
Abstract
Introduction: Artesunate, a derivative of artemisinin, has anti-malarial effects, and in recent years has also been reported to have anti-tumor activity. However, its anti-tumor mechanisms are not well understood.Methods: In this study, we focused on the targeting of Hsp90 by artesunate to inhibit tumor cell proliferation, which we examined using immunoprecipitation, a proliferation assay, flow cytometry, western blotting, a tumor xenograft animal model, and immunohistochemistry. Furthermore, to examine the tumor-suppressive effects of artesunatein nude mice, we used artesunate-loaded PLGA-PEG nanoparticles.Results: The binding of artesunate to Hsp90 was found to reduce the expression of its client proteins AKT, ERK, p-AKT, p-ERK, and EGFR, thereby blocking the cell cycle at the G0/G1 → S stage in lymphoma cells and inducing apoptosis. In addition, the results of tumor xenograft experiments revealed that artesunate reduced the expression of AKT and ERK proteins in tumor tissues, inhibited tumor proliferation, and reduced tumor size and weight. Furthermore, nanoparticle encapsulation was demonstrated to enhance the anti-cancer activity of artesunate.Discussion: We thus established that artesunate inhibits the proliferation of lymphoma cells by targeting the Hsp90 protein, and we accordingly believe that this compound has potential for development as a novelanti-tumor drug.Keywords
This publication has 37 references indexed in Scilit:
- Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signalingAnti-Cancer Drugs, 2014
- NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial MetastasesClinical Cancer Research, 2013
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsNature, 2012
- The discovery of artemisinin (qinghaosu) and gifts from Chinese medicineNature Medicine, 2011
- The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell linesInternational Journal of Cancer, 2009
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKBlood, 2009
- Artemisinins: their growing importance in medicineTrends in Pharmacological Sciences, 2008
- Toxicokinetics and Hydrolysis of Artelinate and Artesunate in Malaria-Infected RatsInternational Journal of Toxicology, 2005
- Targeting HER1/EGFR: A molecular approach to cancer therapySeminars in Oncology, 2003
- Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrinCancer Letters, 1995